Avidity Biosciences granted FDA Fast Track designation for AOC 1044 for treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping. News release. Avidity Biosciences. April 24 ...

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle ...

Duchenne Muscular Dystrophy is a progressive disorder that typically causes boys to lose the ability walk around age 10 and kills them a decade later.

DMD was first described by French neurologist Guillaume Benjamin Amand Duchenne in the 1860s. However, until the 1980s, little was known about the causes of any type of muscular dystrophy.

Duchenne muscular dystrophy (DMD) is a genetic disease that causes progressive muscle weakness. DMD commonly affects boys, where symptoms are seen in early childhood. There is no cure for DMD.

Duchenne muscular dystrophy causes progressive muscle weakness that can rob children of their ability to walk by the time they’re teenagers, and many don’t live well into their 30s.

The Food and Drug Administration (FDA) has granted Fast Track designation to RGX-202 for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in progressive ...

Duchenne muscular dystrophy causes progressive muscle weakness that can rob children of their ability to walk by the time they’re teenagers, and many don’t live well into their 30s.

The Muscular Dystrophy Association trusts the decision of the FDA, which weighs the risks and benefits of the drug. Skip to content. NOWCAST WXII 12 News at 8 a.m. Saturday.